| Title |
|
|
|
BDCA1+CD14+ immunosuppressive cells in cancer, a potential target?
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the tumor site. We hypothesize that BDCA1+CD14+ cells are present in a broad spectrum of cancers and demand further investigation to reveal treatment opportunities and/or improvement for DC vaccines. In this review, we summarize the findings on BDCA1+CD14+ cells in solid cancers. In addition, we evaluate the presence of BDCA1+CD14+ cells in leukemic cancers. Preliminary results suggest that the presence of BDCA1+CD14+ cells correlates with clinical features of acute and chronic myeloid leukemia. Future research focusing on the differentiation from monocytes towards BDCA1+CD14+ cells could reveal more about their cell biology and clinical significance. Targeting these cells in cancer patients may improve the outcome of cancer immunotherapy. |
| |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Vaccines | |
| Publication |
|
|
|
Basel : Mdpi, 2018
| |
| ISSN |
|
|
|
2076-393X
| |
| Volume/pages |
|
|
|
6:3(2018), 10 p.
| |
| Article Reference |
|
|
|
65
| |
| ISI |
|
|
|
000448337100004
| |
| Pubmed ID |
|
|
|
30235890
| |
| Medium |
|
|
|
E-only publicatie
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (open access) |
|
|
| | |
|